This effect in a mouse model was seen within 14 days, most pronounced with a single dose of CEL-1000 at day 0 and resulted in up to a 40% increase in antibody signal at day 28. Also, the timing of the CEL-1000 administration had significant impact on the type of immune response that was created, as well as its strength. CEL-1000 appears to be able to mount a faster immune response, something necessary for a bio defense or a pandemic flu setting, as well as the potential ability to create more effective immune responses through the use of CEL-1000 as an adjuvant.
The data were presented by Dr Daniel Zimmerman, senior vice president of research, cellular immunology at CEL-SCI and involved a collaboration with scientists at several other institutions including Drs. Kenneth Rosenthal Professor of Microbiology and Immunology at Northeastern Ohio Universities Colleges of Medicine and Pharmacy (NEOUCOM), Rootstown, Ohio, Frank Klotz of Biocon, Rockville, Maryland, Peter Blackburn and Steve Grimes of Mercia-Pharma, New York.
Dr Zimmerman said: “These findings are important not just for our CEL- 1000 adjuvant, but also for any adjuvant because our work has shown that the timing of the use of the adjuvant and how often it is given have significant influence on the type and strength of the immune responses elicited.”